Last updated on October 2017

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I


Brief description of study

This study will evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed dose combination (FDC) after switching from a stable regimen consisting of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) plus a third antiretroviral agent in participants harboring the archived nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance mutation M184V and/or M184I in HIV-1 reverse transcriptase.

Clinical Study Identifier: NCT02616029

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Gilead Study Team

Southern California Men's Medical Group
Los Angeles, CA United States
  Connect »

Gilead Study Team

Gary Richmond, MD, PA, Inc.
Fort Lauderdale, FL United States
  Connect »

Gilead Study Team

Midway Immunology & Research Center, LLC
Fort Pierce, FL United States
  Connect »

Gilead Study Team

Orlando Immunology Center
Orlando, FL United States
  Connect »

Gilead Study Team

Triple O Research Institute PA
West Palm Beach, FL United States
  Connect »

Gilead Study Team

Chatham County Health Department
Savannah, GA United States
  Connect »

Gilead Study Team

Southampton Healthcare, Inc.
Saint Louis, MO United States
  Connect »

Gilead Study Team

Southwest CARE Center
Santa Fe, NM United States
  Connect »

Gilead Study Team

Peter Shalit, MD
Seattle, WA United States
  Connect »

Gilead Study Team

Premier Clinical Research
Spokane, WA United States
  Connect »

Gilead Study Team

Hopital Sainte Marguerite - Hospital
Marseille, France
  Connect »

Gilead Study Team

CHU de Nantes
Nantes, France
  Connect »

Gilead Study Team

CHU de Nice-l Archet
Nice, France
  Connect »

Gilead Study Team

CHR Orleans la Source
Orleans, France
  Connect »

Gilead Study Team

Hopital Saint Louis
Paris Cedex 10, France
  Connect »

Gilead Study Team

CHU Hotel Dieu
Paris Cedex 14, France
  Connect »

Gilead Study Team

Hopital Necker les Enfants Malades
Paris Cedex 15, France
  Connect »

Gilead Study Team

Hopital Lariboisiere
Paris, France
  Connect »

Gilead Study Team

H pital Haut-L v que - Service M decine Interne
Pessac, France
  Connect »

Gilead Study Team

CHU Tours Service de M decine Internes et Maladies Infectieuses
Tours, France
  Connect »

Gilead Study Team

Universitatsklinikum Essen
Essen, Germany
  Connect »

Gilead Study Team

Infektiologikum Frankfurt
Frankfurt, Germany
  Connect »

Gilead Study Team

ICH Study Center- Dedicated Research
Hamburg, Germany
  Connect »

Gilead Study Team

Universitat Mainz
Mainz, Germany
  Connect »

Gilead Study Team

IRCCS A.O.U. San Martino
Genova, Italy
  Connect »

Gilead Study Team

Dipartimento di Malattie Infettive e Tropicali dell'Universit di Milano
Milano, Italy
  Connect »

Gilead Study Team

Fondazione IRCCS San Raffaele del Monte Tabor
Milano, Italy
  Connect »

Gilead Study Team

Universit degli Studi di Roma Tor Vergata
Roma, Italy
  Connect »

Gilead Study Team

Dipartimento di Malattie Infettive e Tropicali
Torino, Italy
  Connect »

Gilead Study Team

Hospital Universitari Germans Trias i Pujol
Badalona, Spain
  Connect »

Gilead Study Team

Hospital Clinic de Barcelona - Hospital
Barcelona, Spain
  Connect »

Gilead Study Team

Hospital Universitario 12 de Octubre - Hospital
Madrid, Spain
  Connect »

Gilead Study Team

Hospital Universitario La Paz
Madrid, Spain
  Connect »

Gilead Study Team

Hospital Regional Universitario De M laga
Malaga, Spain
  Connect »

Gilead Study Team

Hospital General Universitario de Valencia
Valencia, Spain
  Connect »

Gilead Study Team

Complexo Hospitalario Universitario De Vigo - Hospital Alvaro Cunqueiro Servicio de Medicina Interna
Vigo, Spain
  Connect »